Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-09-18 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
2025 INTERIM REPORT
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT 2025' for CSPC Pharmaceutical Group Limited. It contains comprehensive financial statements (Income Statement, Statement of Financial Position, Cash Flows), notes to the financial statements, and a detailed Management Discussion and Analysis (MDA) section covering the six-month period ended 30 June 2025. It is a full interim report, not an announcement or a summary. H1 2025
2025-09-18 English
LETTER TO NEW REGISTERED SHAREHOLDERS AND REPLY FORM
Regulatory Filings Classification · 0% confidence The document is a letter to new registered shareholders regarding the election of means of receipt of future corporate communications. It is not a financial report, proxy statement, dividend notice, capital transaction, or other specialized filing category. It serves as a general shareholder communication and thus falls under the fallback category of miscellaneous regulatory announcements (RNS).
2025-09-18 English
VOLUNTARY ANNOUNCEMENT - ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug candidate in China. It does not present financial results, shareholder votes, board changes, or other specific filing types. It is not a report itself but a regulatory announcement of business development. Thus, it best fits the fallback category of General Regulatory Filings (RNS).
2025-09-15 English
VOLUNTARY ANNOUNCEMENT - SYH2066 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by CSPC Pharmaceutical regarding regulatory approval for clinical trials of a new drug. It is not a financial report, earnings release, board/management change, nor any other specific category, so it falls under the general regulatory announcement/fallback category.
2025-09-12 English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR KN026 (ANBENITAMAB INJECTION) ACCEPTED BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement published on the Hong Kong Stock Exchange regarding the acceptance of a new drug application by the NMPA. It is not a financial report, earnings release, AGM materials, management change, or any of the more specific categories. It is a general regulatory announcement about product development. This fits the fallback category “Regulatory Filings (RNS)” for miscellaneous regulatory or corporate announcements.
2025-09-11 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares and treasury shares, specifically detailing the issue of new shares under a share award scheme. This is a regulatory notice of shares being issued (and potentially repurchased/sold), fitting the description “Transaction in Own Shares” (company buying back or selling its own shares or issuing shares). Therefore, the appropriate filing classification is POS (Transaction in Own Shares).
2025-09-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.